MELVILLE, N.Y., Dec. 17 /PRNewswire/ -- Today, the specialty pharmaceutical manufacturer Fougera announced the introduction of two new FDA approved products: Halobetasol Cream 0.05% (Rx) and Ointment 0.05% (Rx). Both are AB rated to Ultravate(R) by Westwood-Squibb(R), and both are available in 15 g and 50 g tubes. (See product package insert for full prescribing information.)
(Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20041217/NYF089 )
David Klaum, Vice President of Sales and Marketing, stated, "Today Fougera has delivered another high potency steroid formulation to market in two preferred topical presentations. Our ability to meet the market demand with multiple presentations is a perfect example of Fougera's overall capability to support both the health care industry, and the patients who depend on topical generics."
As a specialty pharmaceutical manufacturer of topical steroids, antibiotics and antifungal products, as well as ophthalmics, Fougera has received more topical generic FDA approvals than any other company during the past six years. This ability to provide a continuing stream of new products benefits both health care providers seeking multi-source alternatives with the ability to reduce health care costs, and patients whose conditions warrant their application.
For more information on Fougera's complete line of topicals, or any other quality Fougera product, please call Fougera Customer Service at (800) 645-9833. Or visit the company online at http://www.fougera.com/.
Fougera is a leading manufacturer and distributor of a wide range of multi-source topical and ophthalmic pharmaceuticals, in both prescription and over-the-counter dosage forms.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20041217/NYF089
AP PhotoExpress Network: PRN15PRN Photo Desk, email@example.comFougera
CONTACT: Press Contact, Nicole Smith of HLD/Blankman Public Relations,+1-516-536-6811, firstname.lastname@example.org, for Fougera